Ireland· IE-PA-EU/1/24/1800/001
Zynyz 500 mg concentrate for solution for infusion
A retifanlimab product containing retifanlimab, registered in Ireland by Incyte Biosciences Distribution B.V.. The same ATC class is registered in 10 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Retifanlimab is registered in 10 of 19 countries.
Countries holding a registration under ATC L01FF10 (retifanlimab), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 7 of them publish a price we can compare per daily dose
Retifanlimab · ATC L01FF10
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
HPRA (Ireland)- Active substance
- Retifanlimab
- Manufacturer
- Incyte Biosciences Distribution B.V.
- Country
- Ireland (IE)
- ATC code
- L01FF10
- ATC class
- Retifanlimab
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/24/1800/001
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Retifanlimab in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumZynyz 500 mgIncyte Biosciences Distribution
- CzechiaZYNYZIncyte Biosciences Distribution B.V., Amsterdam
- FinlandZYNYZIncyte Biosciences Distribution B.V.
- IcelandZynyzIncyte Biosciences Distribution B.V.
- SwedenZYNYZ 500 mg Koncentrat till infusionsvätska, lösningIncyte Biosciences Distribution B.V.
- United StatesZYNYZIncyte Corporation
- SwitzerlandZYNYZ 500 mg/20 ml, solution à diluer pour perfusionIncyte Biosciences International Sàrl
- SpainZYNYZ 500 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONIncyte Biosciences Distribution B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zynyz
- Liechtenstein · Zynyz
- Norway · Zynyz
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/26a68bb7-8fb8-4369-8d20-0da65f6d6e61 GET /v1/drugs/26a68bb7-8fb8-4369-8d20-0da65f6d6e61?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentrate for solution for infusion",
"routes": [
"Intravenous use"
],
"source": "hpra",
"atc_all": [
"L01FF10"
],
"strength": null,
"pa_number": "EU/1/24/1800/001",
"substances": [
"Retifanlimab"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "19/04/2024",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about retifanlimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.